Roche sales and marketing update

The U.K.’s NICE issued draft guidance recommending against the use of Perjeta pertuzumab from Roche in combination with the pharma’s Herceptin trastuzumab and docetaxel for the neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early stage breast cancer -- its approved indication. According to NICE, there was “uncertainty” about whether a pathological complete response (pCR) with neoadjuvant treatment “was the sole and most reliable indicator of, or translated directly into, treatment-related long-term event-free and overall survival benefit.” ...